Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

Abstract Background Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). P...

Descrición completa

Detalles Bibliográficos

Principais autores:	Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon, François-Clément Bidard
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2021-03-01
Series:	Breast Cancer Research
Assuntos:	Circulating tumor DNA Breast cancer Palbociclib-fulvestrant Treatment follow-up Precision medicine
Acceso en liña:	https://doi.org/10.1186/s13058-021-01411-0
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!